HIVandHepatitis.com coverage of the 15th European AIDS Conference, sponsored by the European AIDS Clinical Society (EACS), October 21-14, 2015, in Barcelona.
Conference highlights include antiretroviral therapy and treatment strategies, new European HIV treatment guidelines, HIV pre-exposure prophylaxis (PrEP), and treatment for hepatitis C.
HIVandHepatitis.com coverage of the 50th European Association for the Study of the Liver International Liver Congress (EASL 2015) in Vienna, April 22-26, 2015.
Conference highlights include interferon-free hepatitis C treatment for people with advanced disease, experimental HCV antivirals, hepatitis B and delta, and management of liver disease complications.
The Department of Health and Human (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents has added the recently approved Genvoya single-tablet regimen containing elvitegravir and the new tenofovir alafenamide to its list of recommended regimens for initial HIV treatment.
Dual antiretroviral regimens consisting of only a boosted HIV protease inhibitor (lopinavir/ritonavir or atazanavir) and a single inexpensive and well-tolerated NRTI may be enough to achieve and maintain HIV suppression in a most patients starting antiretroviral therapy (ART) for the first time or switching from a standard triple regimen, according to a pair of studies presented at the EACS 15th European AIDS Conference last month in Barcelona.